Incyte Lifts 2026 Sales Outlook as Q3 Revenue Climbs 14% to $1.56B
INCY sits 40% above its 52-week low of $84.02.
Summary
Incyte raised full-year 2026 total net sales guidance to $5.21-$5.30 billion from $5.13-$5.26 billion, with Opzelura lifted to $1.10-$1.12 billion and the Hematology/Oncology portfolio to $890-$910 million. Q3 total revenue rose 14% to $1.56 billion, led by Opzelura at $255 million (+36%), Jakafi at $827 million (+4%) and the H&O portfolio at $235 million (+38%). The headline GAAP loss of $784.8 million, or $3.86 per share, is almost entirely the one-time $1.23 billion IPR&D charge from the July Vega Therapeutics acquisition; excluding it, R&D rose 11% and operating income grew 18%, and the adjusted loss per share was $3.60. Cash and marketable securities stand at $3.9 billion, up from $3.6 billion at year-end. The quarter also carried pipeline news: a Phase 3 mutCALR study (EXCALIBUR-MF2) starts by year-end, povorcitinib has a CHMP positive opinion with an EU decision due in Q4 and a potential U.S. launch in Q1 2027, and Monjuvi is under review for newly diagnosed DLBCL with a potential Q1 2027 U.S. approval. Q4 2026 readouts to watch: Phase 1 mutCALR data, TRuE-HS1/HS2 hidradenitis suppurativa topline, and STOP-PN1/PN2 prurigo nodularis data.
At the time of this announcement, INCY was trading at $117.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $84.02 to $132.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.